These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 25613299)

  • 21. Design of Idiopathic Pulmonary Fibrosis Clinical Trials in the Era of Approved Therapies.
    Kaner RJ; Bajwa EK; El-Amine M; Gorina E; Gupta R; Lazarus HM; Luckhardt TR; Mouded M; Posada K; Richeldi L; Stauffer J; Tutuncu A; Martinez FJ
    Am J Respir Crit Care Med; 2019 Jul; 200(2):133-139. PubMed ID: 30985215
    [No Abstract]   [Full Text] [Related]  

  • 22. Evaluating new treatment options.
    Nathan SD
    Am J Manag Care; 2017 Jul; 23(11 Suppl):S183-S190. PubMed ID: 28978213
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Current approaches to the management of idiopathic pulmonary fibrosis.
    Raghu G; Richeldi L
    Respir Med; 2017 Aug; 129():24-30. PubMed ID: 28732832
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Idiopathic pulmonary fibrosis: the turning point is now!
    Funke M; Geiser T
    Swiss Med Wkly; 2015; 145():w14139. PubMed ID: 26024356
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Idiopathic pulmonary fibrosis and pirfenidone.
    Collard HR
    Eur Respir J; 2010 Apr; 35(4):728-9. PubMed ID: 20356985
    [No Abstract]   [Full Text] [Related]  

  • 26. Treating idiopathic pulmonary fibrosis: current opportunities and future challenges.
    Richeldi L
    Clin Respir J; 2012 Jul; 6(3):129-30. PubMed ID: 22697263
    [No Abstract]   [Full Text] [Related]  

  • 27. New therapeutic targets in idiopathic pulmonary fibrosis. Aiming to rein in runaway wound-healing responses.
    Ahluwalia N; Shea BS; Tager AM
    Am J Respir Crit Care Med; 2014 Oct; 190(8):867-78. PubMed ID: 25090037
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recommendations for perioperative management of new pharmacological antifibrotic therapy in idiopathic pulmonary fibrosis.
    González Larrocha O; Romero Rojano P; Ortega Mera U; Arízaga Maguregui A
    Rev Esp Anestesiol Reanim (Engl Ed); 2018 Mar; 65(3):178-179. PubMed ID: 29183632
    [No Abstract]   [Full Text] [Related]  

  • 29. Administration of nintedanib after discontinuation for acute exacerbation of idiopathic pulmonary fibrosis: a case report.
    Ikeda S; Sekine A; Baba T; Yamakawa H; Morita M; Kitamura H; Ogura T
    BMC Pulm Med; 2016 Mar; 16():38. PubMed ID: 26940352
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pirfenidone treatment in idiopathic pulmonary fibrosis: too much of a great expectation?
    Papiris SA; Kagouridis K; Kolilekas L; Triantafillidou C; Tsangaris I; Manali ED
    Eur Respir J; 2012 Sep; 40(3):794-5. PubMed ID: 22941551
    [No Abstract]   [Full Text] [Related]  

  • 31. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis.
    Richeldi L; Costabel U; Selman M; Kim DS; Hansell DM; Nicholson AG; Brown KK; Flaherty KR; Noble PW; Raghu G; Brun M; Gupta A; Juhel N; Klüglich M; du Bois RM
    N Engl J Med; 2011 Sep; 365(12):1079-87. PubMed ID: 21992121
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pirfenidone treatment of idiopathic pulmonary fibrosis.
    Azuma A
    Ther Adv Respir Dis; 2012 Apr; 6(2):107-14. PubMed ID: 22333982
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Resolving the scar of pulmonary fibrosis.
    Downey GP
    N Engl J Med; 2011 Sep; 365(12):1140-1. PubMed ID: 21992127
    [No Abstract]   [Full Text] [Related]  

  • 34. Switching to nintedanib after discontinuation of pirfenidone due to adverse events in IPF.
    Milger K; Kneidinger N; Neurohr C; Reichenberger F; Behr J
    Eur Respir J; 2015 Oct; 46(4):1217-21. PubMed ID: 26341986
    [No Abstract]   [Full Text] [Related]  

  • 35. Idiopathic Pulmonary Fibrosis.
    Lederer DJ; Martinez FJ
    N Engl J Med; 2018 May; 378(19):1811-1823. PubMed ID: 29742380
    [No Abstract]   [Full Text] [Related]  

  • 36. Pirfenidone for the treatment of idiopathic pulmonary fibrosis.
    George PM; Wells AU
    Expert Rev Clin Pharmacol; 2017 May; 10(5):483-491. PubMed ID: 28266906
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Novel therapies for idiopathic pulmonary fibrosis].
    Wand O; Kremer MR
    Harefuah; 2015 Jul; 154(7):446-50, 469, 468. PubMed ID: 26380465
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Idiopathic pulmonary fibrosis: lessons from clinical trials over the past 25 years.
    Raghu G
    Eur Respir J; 2017 Oct; 50(4):. PubMed ID: 29074545
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FDA panel likes new treatment for idiopathic pulmonary fibrosis.
    Morrow T
    Manag Care; 2010 Apr; 19(4):53-4. PubMed ID: 20446566
    [No Abstract]   [Full Text] [Related]  

  • 40. Idiopathic pulmonary fibrosis: an update.
    Spagnolo P; Sverzellati N; Rossi G; Cavazza A; Tzouvelekis A; Crestani B; Vancheri C
    Ann Med; 2015 Feb; 47(1):15-27. PubMed ID: 25613170
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.